Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin

Burmeister, B., Walpole, E. T., Burmeister, E., Thomas, J., Thomson, D. B., Harvey, J., Smithers, B. M. and Gotley, D. C. (2005) Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin. International Journal of Clinical Oncology, 10 4: 256-261. doi:10.1007/s10147-005-0506-9


Author Burmeister, B.
Walpole, E. T.
Burmeister, E.
Thomas, J.
Thomson, D. B.
Harvey, J.
Smithers, B. M.
Gotley, D. C.
Title Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin
Journal name International Journal of Clinical Oncology   Check publisher's open access policy
ISSN 1341-9625
Publication date 2005-01-01
Sub-type Article (original research)
DOI 10.1007/s10147-005-0506-9
Open Access Status Not yet assessed
Volume 10
Issue 4
Start page 256
End page 261
Total pages 6
Editor M. Hiraoka
Place of publication Japan
Publisher Springer-Verlag Tokyo
Subject C1
321015 Oncology and Carcinogenesis
730108 Cancer and related disorders
Abstract Chemoradiation therapy is the standard treatment for esophageal cancer in patients not fit for surgery. The regimen most commonly used includes cisplatin and 5-fluorouracil. Little data exists regarding alternative chemotherapy regimens in patients not suitable for cisplatin. We report on a regimen using protracted infusion 5-fluorouracil alone for both curative and palliative indications.

Twenty-two patients with localized esophageal cancer suitable for curative chemoradiation therapy and 24 patients suitable for palliative therapy were enrolled. Chemotherapy consisted of 5-fluorouracil 225 mg/m(2) daily throughout the radiation therapy. The radiation dose was 56 to 60 Gy in 28 to 30 fractions (curative patients) and 30 to 35 Gy in 15 fractions (palliative patients).

The median age of the patients was 75 years. The regimen was tolerable. Significant grade 3 toxicities experienced were esophagitis (11%) and venous catheter toxicity (9%). The median survival was 17 months for curative patients and 9 months for palliative patients. The complete response rate was 86% endoscopically and 45% radiologically for curative patients. Relief of dysphagia was experienced in 67% of palliative patients. Quality of life was satisfactory in both groups.

This study showed that continuous-infusion 5-fluorouracil given concurrently with radiation therapy is a useful alternative to platinum-based chemoradiation therapy in patients with esophageal carcinoma.
Q-Index Code C1
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
2006 Higher Education Research Data Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 12 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 15:38:13 EST